Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics, Inc. is pursuing a primary offering of its common stock under a shelf prospectus supplement subject to completion. The prospectus does not state the number of shares or offering size; net proceeds are intended for general corporate purposes, including research and development and working capital. The company reported approximately $496 million in cash, cash equivalents and investments as of March 31, 2026, and had 48,722,309 shares of common stock outstanding as of December 31, 2025. The common stock trades on Nasdaq under the symbol ORKA and the prospectus includes customary underwriting terms, a 30-day option to purchase additional shares, a 45-day lock-up period for insiders, and standard offering risk disclosures.
Oruka Therapeutics, Inc. is pursuing a primary offering of its common stock under a shelf prospectus supplement subject to completion. The prospectus does not state the number of shares or offering size; net proceeds are intended for general corporate purposes, including research and development and working capital. The company reported approximately $496 million in cash, cash equivalents and investments as of March 31, 2026, and had 48,722,309 shares of common stock outstanding as of December 31, 2025. The common stock trades on Nasdaq under the symbol ORKA and the prospectus includes customary underwriting terms, a 30-day option to purchase additional shares, a 45-day lock-up period for insiders, and standard offering risk disclosures.
Oruka Therapeutics, Inc. is offering securities under a preliminary prospectus supplement related to a shelf registration covering up to $500,000,000 of common stock and pre-funded warrants. The offering includes common stock and pre-funded warrants exercisable at $0.001 per share, with the shares issuable upon exercise registered here.
The prospectus supplement states 48,722,309 shares outstanding as of December 31, 2025 and discloses a preliminary cash, cash equivalents and investments balance of approximately $496 million as of March 31, 2026. Net tangible book value was reported as $471.9 million, or $9.69 per share, as of December 31, 2025. The offering proceeds treatment is described as for general corporate purposes, including research and development and working capital.
Oruka Therapeutics, Inc. is offering securities under a preliminary prospectus supplement related to a shelf registration covering up to $500,000,000 of common stock and pre-funded warrants. The offering includes common stock and pre-funded warrants exercisable at $0.001 per share, with the shares issuable upon exercise registered here.
The prospectus supplement states 48,722,309 shares outstanding as of December 31, 2025 and discloses a preliminary cash, cash equivalents and investments balance of approximately $496 million as of March 31, 2026. Net tangible book value was reported as $471.9 million, or $9.69 per share, as of December 31, 2025. The offering proceeds treatment is described as for general corporate purposes, including research and development and working capital.
Oruka Therapeutics reported interim Phase 2a EVERLAST-A results for ORKA-001 in moderate-to-severe plaque psoriasis, showing 63.5% (40/63) of treated patients reached PASI 100, versus 4.8% (1/21) on placebo at Week 16.
Secondary measures were similarly strong, with 82.5% achieving PASI 90 and 84.1% reaching IGA 0/1. ORKA-001’s safety profile was comparable to placebo, with no serious treatment-emergent adverse events in the active arm and no injection site reactions. Phase 1 pharmacokinetic and pharmacodynamic data indicate drug levels and IL‑23 pathway inhibition remain above effective thresholds for a year after a single 600 mg dose, supporting potential once‑yearly dosing. The EVERLAST-A trial continues, with longer-term durability and safety data expected in the second half of 2026, while the dose-ranging Phase 2b EVERLAST-B study is enrolling, with results anticipated in 2027.
Oruka Therapeutics reported interim Phase 2a EVERLAST-A results for ORKA-001 in moderate-to-severe plaque psoriasis, showing 63.5% (40/63) of treated patients reached PASI 100, versus 4.8% (1/21) on placebo at Week 16.
Secondary measures were similarly strong, with 82.5% achieving PASI 90 and 84.1% reaching IGA 0/1. ORKA-001’s safety profile was comparable to placebo, with no serious treatment-emergent adverse events in the active arm and no injection site reactions. Phase 1 pharmacokinetic and pharmacodynamic data indicate drug levels and IL‑23 pathway inhibition remain above effective thresholds for a year after a single 600 mg dose, supporting potential once‑yearly dosing. The EVERLAST-A trial continues, with longer-term durability and safety data expected in the second half of 2026, while the dose-ranging Phase 2b EVERLAST-B study is enrolling, with results anticipated in 2027.
ORKA filed a prospectus supplement to amend the selling stockholders table: the resale registration still covers 39,425,806 shares of Common Stock, and SILV Fund Ltd. is substituted for Point72 Associates, LLC as a selling stockholder. The supplement cites 49,542,691 shares outstanding as of February 28, 2026 for percentage calculations and shows 531,670 shares listed for SILV Fund Ltd. The supplement does not increase the number of shares registered and repeats the stated market price of $68.87 per share (last reported sale on April 20, 2026).
Oruka Therapeutics, Inc. has issued its 2026 proxy statement for a virtual annual meeting on June 2, 2026, where stockholders will elect two Class II directors, ratify PricewaterhouseCoopers LLP as auditor, and cast a non-binding advisory vote on executive pay. The record date is April 7, 2026, with 50,196,914 common shares entitled to one vote each. The board is classified into three staggered classes and recommends voting FOR all proposals. The filing also details governance practices, director and executive biographies, director compensation, and 2025 pay for the CEO and other named executive officers.
Oruka Therapeutics Chief Medical Officer Joana Goncalves exercised employee derivatives and sold shares in a routine, pre-planned transaction. She exercised 3,500 employee stock options at $6.84 per share and 3,500 employee warrants at $7.80 per share, receiving 7,000 shares of common stock.
On the same date, she sold 7,000 common shares in open-market transactions at weighted average prices of $65.73, $66.56 and $67.38, pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. Following these trades, she directly holds 33,377 shares of Oruka Therapeutics common stock, along with substantial remaining options and warrants.
ORKA reported Rule 144 sale notices and option-related transactions on 04/15/2026. The filing lists an exercise of stock options resulting in 21,000 shares delivered for cash on 04/15/2026. The record also shows multiple prior 10b5-1 sales during March and February totaling reported cash amounts.
Oruka Therapeutics, Inc. filed a shelf registration to offer up to $1,000,000,000 of common stock, preferred stock, depositary shares and warrants, to be sold from time to time in one or more offerings. The prospectus states securities may be sold directly, through agents or underwriters, on a continuous or delayed basis, with specific terms provided in prospectus supplements. The company’s common stock trades on the Nasdaq Global Market under the symbol ORKA, with a reported last sale price of $50.43 per share on April 1, 2026. The prospectus incorporates by reference the company’s periodic reports and risk factors, and notes that use of proceeds, pricing, and underwriting terms will be set forth in future prospectus supplements.